Idacta-mab INT-001 represents an promising therapeutic approach for treating selected oncological tumors. This antibody demonstrates an special process of action, particularly interacting with the CD38 antigen, an exterior antigen present widely on multiple blood-forming cells. Preliminary patien… Read More

Enoblituzumab, previously known as TJ-271 or MGA271, represents the innovative monoclonal specific to CD33, an marker found predominantly on myeloid populations. Such molecule functions as a bispecific molecule, at once connecting to CD33 on cancerous cells and to a CD3 molecule, a component of a… Read More

Tepotinib, also known as {MSC2156119|the experimental compound|this agent), represents a significant breakthrough in the management of non-small cell lung cancer, particularly in those harboring MET exon 14 mutations. This selective tyrosine kinase agent|TKI shows remarkable effect against cancer… Read More

Compound E, chemically designated as the compound 209986-17-4, represents a significant exploration within the field of Alzheimer's disease research. This γ-secretase blocking agent was initially developed as a possible therapeutic treatment aimed at reducing the generation of amyloid-beta peptid… Read More